TY - JOUR
T1 - Stereochemistry at the forefront in the design and discovery of novel anti-tuberculosis agents
AU - Huang, Qingqing
AU - He, Rong
AU - Kozikowski, Alan P.
PY - 2011/4/1
Y1 - 2011/4/1
N2 - Today, 75% of new drugs introduced to the market are single enantiomers and new techniques in asymmetric synthesis and chiral separation expedites chiral drug discovery and development worldwide. The enantiomers of a chiral drug present unique chemical and pharmacological behaviors in a chiral environment, such as the human body, in which the stereochemistry of chiral drugs determines their pharmacokinetic, pharmacodynamic, and toxicological actions. Thus, it is imperative that only the pure and therapeutically active isomer be prepared and marketed. Tuberculosis (TB), a highly contagious and airborne disease that is caused by infection with Mycobacterium tuberculosis (Mtb), currently represents one of the most threatening health problems globally. The emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), as well as HIV co-infection along with a lengthy treatment regimen, highlights an urgent need for the development of new anti-TB agents. Currently, new chiral anti-TB agents are being developed from some well-known anti-TB agents, high throughput screening (HTS) hits, and natural products. This review will focus on the reported chiral anti-TB agents together with the clinical importance of their chirality and stereochemistry.
AB - Today, 75% of new drugs introduced to the market are single enantiomers and new techniques in asymmetric synthesis and chiral separation expedites chiral drug discovery and development worldwide. The enantiomers of a chiral drug present unique chemical and pharmacological behaviors in a chiral environment, such as the human body, in which the stereochemistry of chiral drugs determines their pharmacokinetic, pharmacodynamic, and toxicological actions. Thus, it is imperative that only the pure and therapeutically active isomer be prepared and marketed. Tuberculosis (TB), a highly contagious and airborne disease that is caused by infection with Mycobacterium tuberculosis (Mtb), currently represents one of the most threatening health problems globally. The emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), as well as HIV co-infection along with a lengthy treatment regimen, highlights an urgent need for the development of new anti-TB agents. Currently, new chiral anti-TB agents are being developed from some well-known anti-TB agents, high throughput screening (HTS) hits, and natural products. This review will focus on the reported chiral anti-TB agents together with the clinical importance of their chirality and stereochemistry.
KW - Anti-tuberculosis agents
KW - Chiral drugs
KW - Stereochemistry
UR - http://www.scopus.com/inward/record.url?scp=79953660738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953660738&partnerID=8YFLogxK
U2 - 10.2174/156802611795165205
DO - 10.2174/156802611795165205
M3 - Review article
C2 - 21291395
AN - SCOPUS:79953660738
SN - 1568-0266
VL - 11
SP - 810
EP - 818
JO - Current topics in medicinal chemistry
JF - Current topics in medicinal chemistry
IS - 7
ER -